The field of Hepatology has witnessed significant advancements over the past few years. These have revolutionized the management of Hepatitis, a disease that poses a significant global health burden. The advancements have been in diagnostic technologies, antiviral therapies, and preventive strategies.
Highly sensitive and specific molecular diagnostic tools have improved the detection of Hepatitis viruses. These include next-generation sequencing and digital droplet PCR. They have made it possible to identify viral genotypes and subtypes, detect drug resistance mutations, and monitor viral load with greater accuracy.
Antiviral therapy for Hepatitis has seen a paradigm shift with the advent of Direct-Acting Antivirals (DAAs). These drugs target specific steps in the viral life cycle, providing a cure rate of over 90% for Hepatitis C. Similarly, new drugs for Hepatitis B, like tenofovir alafenamide, offer better viral suppression and fewer side effects. Moreover, the development of Hepatitis D specific antivirals is a promising area of research.
Preventive strategies have focused on vaccination and harm reduction. The Hepatitis B vaccine has been incorporated into national immunization programs, significantly reducing the incidence of new infections. For Hepatitis C, harm reduction strategies like needle and syringe programs and opioid substitution therapy have been effective in reducing transmission among people who inject drugs.
The advancements in Hepatitis management have brought us closer to achieving the World Health Organization's goal of eliminating viral hepatitis as a public health threat by 2030. It is imperative for healthcare professionals to stay abreast of these advancements to provide optimal care for patients with Hepatitis.
1.
Researchers found that patients undergoing chemotherapy had a higher risk of mixed infections and should begin antibiotic therapy right away.
2.
Study confirms safety and efficacy of higher-dose-per-day radiation for early-stage prostate cancer
3.
Admissions, medical schools, costs, and eligibility requirements information for FNB Onco-Anesthesia.
4.
Radiation therapy can promote amphiregulin, which increases growth of metastases
5.
High Success Rate With Conversion Therapy for Unresectable Gastroesophageal Cancer
1.
Learning from Uncommon Inherited Bleeding Disorder Presentations
2.
Essential Strategies in Hematology for Healthcare Excellence
3.
An Overview Of Leukemia Cutis: What It Is And How To Treat It
4.
All About Ferric Gluconate – The Best Source Of Iron For Anemia
5.
Lymphomatoid Papulosis: What You Need to Know
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Beyond the Mutation: Addressing the Unmet Needs in ALK-Positive NSCLC
2.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VI
3.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part IV
4.
Exploring Potentials of Lorlatinib: The Third Generation ALK-TKI Through CROWN Trial
5.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part I
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation